Psoriasis vulgaris, Psoriatic arthritis, Pustular psoriasis, Erythrodermic psoriasis
Conditions
Interventions
Endothelial function is measured in patients with psoriasis treated with infliximab before and after the first, second, and third infusions.
Sponsors
The University of Tokyo Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed as having psoriasis vulgaris, psoriatic arthritis, pustular psoriasis, erythrodermic psoriasis 2. Patients at the age of 20 - 80 years when written informed consent is obtained 3. Patients who meet either of the following two criteria; (i) insufficiently treated with systemic therapies including phototherapy and skin lesions covering more than 10% of body surface area, (ii) severe skin and joint symptoms refractory to pre-existing treatments and quality of life is highly disturbed. 4. Patients from whom written informed consent is obtained after the sufficient explanation and understanding of this study
Exclusion criteria
Exclusion criteria: 1. Patients who are treated with other biologics within 3 months 2. Patients treated with cyclosporine within 2 weeks 3. Patients with the past history of severe hypersensitivity or anaphylaxis against infliximab or drugs including murine proteins. 4. Patients with or suspected of having malignancy 5. Patients with serious infection, such as sepsis and positivity of Hepatitis B virus antigen 6. Patients with active or the past history of tuberculosis 7. Patients with active or the past history of demyelinating diseases 8. Patients with congestive heart failure 9. Patients with serious liver diseases (more than 300 IU of AST or ALT) 10. Patients with serious kidney diseases (serum creatinine >= 2.0mg/dl) 11. Patients under or suspected of pregnancy 12. Patients under breast feeding 13. Patients who are regarded to be inappropriate for this study by doctors
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The percentage improvement in reactive hyperemia index measured by EndoPAT at 4 hours after the third infusion compared with the baseline | — |
Countries
Japan
Contacts
Public ContactSatoshi Toyama
The University of Tokyo Hospital Dermatology
Outcome results
None listed